Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Esophageal Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
28 drugs · 167 active trials
6 drugs · 136 active trials
6 drugs · 74 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pegfilgrastim | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2003-09 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-07 |
| Rilotumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2009-02 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | May 17, 2002 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-01 |
| Aflibercept | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-01 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-07 |
| Arsenic Trioxide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-06 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-08 |
| Buparlisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2013 |
| Carboplatin OR Cisplatin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 1, 2020 |
| Cemiplimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 31, 2023 |
| Ceritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2015-12 |
| FOLFOX-6 Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-09 |
| Margetuximab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-01 |
| Mitomycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2001-09 |
| Olaparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 6, 2018 |
| PD1 Inhibitor | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 26, 2021 |
| Pertuzumab/Trastuzumab Regimen | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-01 |
| Raltitrexed | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 5, 2018 |
| Rigosertib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-03 |
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2020 |
| Sorafenib Tosylate | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2009-02 |
| Temozolomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 28, 2021 |
| Elimusertib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 25, 2021 |
| Veliparib | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Jun 20, 2011 |
| Vorinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-11 |
| Ribociclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Jul 30, 2019 |
| Vandetanib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 7, 2008 |
| Akt Inhibitor MK2206 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Alpelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 26, 2013 |
| Azacitidine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-06 |
| Ganetespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 10, 2015 |
| Mogamulizumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-03 |
| Motesanib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-12 |
| Panobinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-09 |
| Porcupine Inhibitor WNT974 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2011 |
| Selinexor | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-12 |
| Sirolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Sonidegib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 10, 2014 |
| Topotecan | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 1995-03 |
| Sorafenib | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | 2006-06 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.